GOSH Enters into Agreement with Leucid Bio at a New Therapy Manufacturing Center

Kadeja Johnson
16 March 2023
Cell Therapy
Clinical Trials
Collaborations, Mergers & Acquisitions
UK based biotech, Leucid Bio, announced an agreement with Great Ormond Street Hospital (GOSH) to manufacture its lead asset CAR-T cell therapy LEU011, for use in human clinical studies.

This first-of-its-kind commercial manufacturing agreement will combine Leucid Bio’s proprietary lateral CAR Platform with GOSH’s specialised manufacturing facilities at the Zayed Centre for Research in Rare Disease in Children.

GOSH will manufacture LEU011, a lateral CAR targeting NKG2D ligands, in patients with solid tumors and hematological malignancies, utilising state-of-the-art cleanroom facilities for the therapy’s first in human study.

Leucid Bio is set to file a clinical trial application (CTA) for initiation in H1 2023, with patient dosing expected to begin by H2 2023, subject to regulatory approval.

How are you enjoying this news article? Let us know your thoughts, here >>


“At Great Ormond Street Hospital, we see children with the most rare and complex cancers […] Gene and cell therapies offer hope for better, and potentially curative treatments which is why we’re excited to support innovation in gene therapies through access to these highly specialist and unique facilities,” comments Stephen Mathew, Head of Innovation at GOSH

For over 20 years, Dr Maher, the Scientific Founder and Chief Scientific Officer of Leucid Bio has worked on Car T-cell – primarily focusing on solid tumors. Leucid Bio has developed the CAR-T model to enhance T-cell potency, provide a long-term response with reduced toxicity by adapting a more natural configuration within the T-cells.

The treatment of solid tumors using CAR T-cell therapy has lacked efficacy in comparison to the proven success of treatment for other refractory blood cancers.

LEU011 has integrated complementary signalling domains parallel across the cell membrane based on the lateral CAR structure. This gives LEU011 the ability to consistently outperform previous generations of CAR T-cells for better control over T-cell activation, superior anti-tumor activity, and a favourable toxicity profile – improving its efficacy.

 “We are pleased to have started a process with GOSH to examine the feasibility of applying our approach in the paediatric setting where there remains a great unmet need for new therapies […] fundamental to our ability to move quickly into clinical trials, using their state-of-the-art manufacturing facilities,” adds Ian Miscampbell, Interim Executive Chairman of Leucid Bio.

Source: Leucid Bio press release


While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.